Literature DB >> 30470842

Downregulation of miR-152 contributes to DNMT1-mediated silencing of SOCS3/SHP-1 in non-Hodgkin lymphoma.

Qing-Ming Wang1, Guang-Yu Lian2, Yuan Song3, Zhi-Da Peng3, Sheng-Hua Xu3, Yi Gong4.   

Abstract

Understanding the molecular mechanisms for the development of non-Hodgkin lymphoma (NHL) will improve our ability to cure the patients. qRT-PCR was applied for the examination of the efficiency of shRNA for DNMT1, the expression of suppressor genes, miRNA-152. The MTT analysis, cell cycle analysis, clonal formation, and apoptotic analysis were used to examine the functions of DNMT1 and miR-152 in lymphoma cells. Methylation-specific polymerase chain reaction (MSP) was used to examine the methylation of tumor suppressor genes. The dual luciferase assay and western blot were used to validate if DNMT1 is the target of miR-152. For the in vivo experiments, the lymphoma cells were injected into the nude mice for quantification of the tumor growth after transfection of miR-152 mimics. Knockdown of DNMT1 by shRNA (sh-DNMT1) in OCI-Ly10 and Granta-159 cells significantly upregulated the expression of tumor suppressor genes (SOCS3, BCL2L10, p16, p14, and SHP-1) via decreasing their methylation level. At the cellular level, we found sh-DNMT1 inhibited the proliferation, clonal formation and cell cycle progression and induced the cell apoptosis of lymphoma cells. Furthermore, we found miR-152 can downregulates the expression of DNMT1 via directly targeting the gene. Overexpression of miR-152 also increased the expression of tumor suppressor genes SOCS3 and SHP-1. And miR-152 also can inhibit the cell proliferation and induce the cell apoptosis. Moreover, we found overexpression of miR-152 significantly repressed the tumor growth with decreased DNMT1 expression and increased expression of tumor suppressor genes in vivo. Our study demonstrates that miR-152 can inhibit lymphoma growth via suppressing DNMT1-mediated silencing of SOCS3 and SHP-1. These data demonstrate a new mechanism for the development of NHL and this may provide a new therapeutic target for NHL.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30470842     DOI: 10.1038/s41417-018-0057-7

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.854


  2 in total

1.  DNA methylation in eukaryotes: kinetics of demethylation and de novo methylation during the life cycle.

Authors:  S P Otto; V Walbot
Journal:  Genetics       Date:  1990-02       Impact factor: 4.562

2.  RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.

Authors:  Padmaja Tummalapalli; Christopher S Gondi; Dzung H Dinh; Meena Gujrati; Jasti S Rao
Journal:  Int J Oncol       Date:  2007-07       Impact factor: 5.650

  2 in total
  9 in total

1.  Epigenetic regulation of miR-518a-5p-CCR6 feedback loop promotes both proliferation and invasion in diffuse large B cell lymphoma.

Authors:  Qian Huang; Feng Zhang; Haiying Fu; Jianzhen Shen
Journal:  Epigenetics       Date:  2020-06-30       Impact factor: 4.528

2.  DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer.

Authors:  Meng Cao; Peng-Bo Zhang; Peng-Fei Wu; Qun Chen; Wan-Li Ge; Guo-Dong Shi; Jie Yin; Bao-Bao Cai; Shou-Ji Cao; Yi Miao; Kui-Rong Jiang
Journal:  Biomed Res Int       Date:  2021-03-02       Impact factor: 3.411

3.  A Survival-Related Competitive Endogenous RNA Network of Prognostic lncRNAs, miRNAs, and mRNAs in Wilms Tumor.

Authors:  HengChen Liu; MingZhao Zhang; ManYu Shi; TingTing Zhang; ZeNan Zhang; QingBo Cui; ShuLong Yang; ZhaoZhu Li
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

4.  SNHG3 Affects Gastric Cancer Development by Regulating SEPT9 Methylation.

Authors:  Wei Li; Xudong Ma; Feng Wang; Shi Chen; Qingxiong Guo; Feng Sun; Yongqing Duan
Journal:  J Oncol       Date:  2022-04-28       Impact factor: 4.501

Review 5.  Critical roles of PTPN family members regulated by non-coding RNAs in tumorigenesis and immunotherapy.

Authors:  Xiaolong Tang; Chumei Qi; Honghong Zhou; Yongshuo Liu
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738

Review 6.  Regulation of DNA methylation machinery by epi-miRNAs in human cancer: emerging new targets in cancer therapy.

Authors:  Mohammad Reza Karimzadeh; Peyman Pourdavoud; Naeim Ehtesham; Mohaddese Qadbeigi; Masood Movahedi Asl; Behrang Alani; Meysam Mosallaei; Bahram Pakzad
Journal:  Cancer Gene Ther       Date:  2020-08-10       Impact factor: 5.987

Review 7.  Overcoming biological barriers to improve solid tumor immunotherapy.

Authors:  Anvay Ukidve; Katharina Cu; Ninad Kumbhojkar; Joerg Lahann; Samir Mitragotri
Journal:  Drug Deliv Transl Res       Date:  2021-02-20       Impact factor: 4.617

8.  THAP9-AS1 Promotes Tumorigenesis and Reduces ROS Generation through the JAK2/STAT3 Signaling Pathway by Increasing SOCS3 Promoter Methylation in Osteosarcoma.

Authors:  Shuai Yang; Bing Wang; Chang Liu; Qizun Wang; Ronghuan Wang; Weiliang Su; Youfu Zhu; Maohua Li; Zhaoyang Guo; Xiaolin Wu; Feng Chen
Journal:  Oxid Med Cell Longev       Date:  2021-10-14       Impact factor: 6.543

Review 9.  Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics.

Authors:  Daniel J García-Domínguez; Lourdes Hontecillas-Prieto; Natalia Palazón-Carrión; Carlos Jiménez-Cortegana; Víctor Sánchez-Margalet; Luis de la Cruz-Merino
Journal:  Cancers (Basel)       Date:  2022-03-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.